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Edited by Maurice MontalAbstract Gene matching shows that Nischarin is a mouse
homologue of human imidazoline receptor antisera-selective
(IRAS) protein, a viable candidate of the imidazoline (I1) recep-
tor. Nischarin and IRAS share the functions of enhancing cell
survival, growth and migration. Bioinformatics modeling indi-
cates that the IRAS and Nischarin may be transmembrane pro-
teins and the convergence information raises the interesting
possibility that Nischarin might serve as the I1-receptor. To test
this hypothesis, we developed antibodies against the Nischarin
protein, and conducted signal transduction (functional) studies
with the I1-receptor agonist rilmenidine in the presence and ab-
sence of Nischarin antisense oligodeoxynucleotides (ODNs).
NIH3T3 cells transfected with the Nischarin cDNA and incu-
bated with the newly synthesized antibody expressed a 190 kD
band. The antibody identiﬁed endogenous Nischarin in diﬀerenti-
ated PC12 cells around 210 kD, which is consistent with reported
ﬁndings in other cells of neuronal origin. The immunoﬂoures-
cence ﬁndings showed the targeted protein to be associated with
the cell membrane in PC12 cells. Nischarin ODNs abolished the
expression of Nischarin in PC12 cells. Equally important, the
Nischarin ODNs eliminated the production of MAPKp42/44, a
recognized signal transduction product generated by I1-receptor
activation in diﬀerentiated PC12 cells. Together, the present
ﬁndings suggest that Nischarin may serve as the functional I1-
receptor or at least share a common signaling pathway in the dif-
ferentiated PC12 cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The imidazoline (I1) receptor is functionally and genetically
distinguished from the a2-adrenergic receptor (a2-AR) [1,2].
Our previous studies established that the I1-receptor activation
with rilmenidine leads to the phosphorylation of the mitogen-
activated protein kinase (MAPKp42/44) in vitro [3] and in vivo
[4]. Therefore, MAPKp42/44 may serve as a marker of, as well
as an intracellular mediator of neurobiological responses elic-
ited by the activation of the I1-receptor [3,4].Abbreviations: a2-AR, a2 adrenergic receptor; DMEM, Dulbecco’s
modiﬁed Eagle’s medium; FBS, fetal bovine serum; FITC, ﬂuorescein;
IRAS, imidazoline receptor antisera-selective; MAPK, mitogen-acti-
vated protein kinase; ODN, oligodeoxynucleotide
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doi:10.1016/j.febslet.2006.04.058The ﬁrst suggested candidate for the I1-receptor protein is
imidazoline receptor antisera-selective (IRAS) whose gene
was cloned from a human hippocampus cDNA expression li-
brary [5,6]. Findings with an antiserum developed by Reis
and co-workers have resulted in the designation imidazoline
receptor binding peptide (IRBP) [7]. Human IRAS (hIRAS,
167 kD) binds many imidazoline compounds and is structur-
ally diﬀerent from the a2-AR. Transfection of hIRAS cDNA
into Chinese Hamster Ovary (CHO) and PC12 cells resulted
in high-aﬃnity I1-receptor like binding sites without appear-
ance of a2-AR or the imidazoline I2 binding site [6,8,9]. Over-
expression of the hIRAS in HEK293 kidney cells led to
activation of ERK [10]. Interestingly, the latter is also acti-
vated by I1-receptor agonists in PC12 cells [3,11] and brain-
stem neurons [4].
Nischarin is the mouse homologue of hIRAS, which was
identiﬁed and cloned by Alahari and coworkers [12]. Nischarin
is truncated at the N-terminal 244 amino acids compared to
the hIRAS. The domain of Nischarin that interacts with the
integrin a5 subunit is comparable to that of the hIRAS
[12,13]. Nischarin aﬀects the signaling of the cytoskeleton reg-
ulated by Rho-family GTPase [12]. However, despite the
homology and the shared signaling between Nischarin and
the IRAS, no study has explored the possibility that Nischarin
might serve as the functional I1-receptor.
In the present study, we tested the hypothesis that Nischarin
serves as, or at least shares a common signaling pathway with,
the I1-receptor. To this end, we developed anti-Nischarin anti-
bodies. We then undertook functional signal transduction
studies that involve I1-receptor signaling in the absence and
presence of antisense or mismatch oligodeoxynucleotide
(ODN) of Nischarin. As a ﬁrst step, we sought evidence to
show that the antisense molecules successfully inhibited the
expression of Nischarin. In the second experiment, we used
the Nischarin antisense, which eﬀectively inhibited Nischarin
expression in PC12 cells, to investigate whether this antisense
could inhibit the signaling triggered by I1-receptor. The latter
was achieved by evaluating the impact of Nischarin ODN on
the generation of MAPKp42/44 in PC12 cells elicited by
I1-receptor activation using rilmenidine at the optimal concen-
tration and incubation time determined in our previous study
[3].2. Material and methods
2.1. Cell culture
PC12 cells (ATCC, Rockville, MD) were cultured, at 37 C with sat-
urated air containing 5% CO2, in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Invitrogen, Carlsbad, CA) supplemented with fetal bovineblished by Elsevier B.V. All rights reserved.
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tomycin (100 lg/ml). Culture dishes (100 mm diameter, Corning, NY)
were coated with poly-lysine (0.1 mg/ml, Sigma–Aldrich, St. Louis,
MO) to promote the cell attachment. Culture media were changed
every 2 days. NIH3T3 cells (NIH Swiss mouse embryonic ﬁbroblast,
ATCC, Rockville, MD) were cultured in DMEM with 10% FBS and
penicillin (100 U/ml), and streptomycin (100 lg/ml). Cell culture media
were changed twice a week.
2.2. Transfection of Nischarin cDNA in NIH3T3 cells
NIH3T3 cells were subcultured in 100 mm culture dish with 60–70%
conﬂuent. The cells were grown in serum and antibiotic free DMEM
for 1 h before the transfection. The expression vector of the full length
myc-tagged Nischarin, pcDNA-myc-Nischarin (a gift from Dr. Alahari)
and the empty vector (control) were transfected into the NIH3T3 cells.
Transfection was processed with a liposome formulation of the poly-
cationic lipid-Lipofectamine (Invitrogen, Carlsbad, CA) according to
the manufacturer’s procedure. The assay of the Nischarin expression
was performed 24 h post-transfection.
2.3. Antiserum production
For production of a potential anti-I1-receptor antibody, a sequence
of the Nischarin protein (Genebank: AAG42100) was used to design
the peptides. For the N-terminal peptide, a sequence from the N-ter-
minal of the Nischarin protein (12–22, EVLAPEASEED) was se-
lected and added the residue of cysteine to the –COOH end of the
peptide. The C-terminal peptide was chosen from the C-terminal se-
quence of the Nischarin sequence (1269–1280, LMGYYPYPQAL)
with the cysteine added at the –NH3 end. The synthetic peptides were
conjugated to keyhole limpet hemacyanin. The rabbit anti-sera were
produced following the protocol approved by the institutional animal
care and use committee. Before the injection of the antigen (conju-
gated peptides) for the immunization, pre-sera were taken from each
animal for later analysis. The ﬁnal bleeding occurred after the fourth
injection. The anti-sera’s titer was examined by enzyme-linked immu-
nosorbent assays (ELISA) [14]. The N-terminal antibody of Nischa-
rin was designated as anti-Nischarin (NT) and C-terminal antibody
as anti-Nischarin (CT).
2.4. Immunoﬂourescence labeling
Immunoﬂourescence labeling was performed as in our previous
studies [3] with some modiﬁcation. PC12 cells were cultured on the
Lab-Tek Chamber Slide coated with poly-lysine. Cells were ﬁxed
with cold 4% paraformaldehyde and the cell membranes were perme-
abilized with 0.3% Triton X-100. The non-speciﬁc binding was blocked
by 1% bovine serum albumin. The cells were incubated with anti-Nis-
charin (NT) (1:250) for 2.5 h at room temperature and then incubated
with ﬂuorescein (FITC) linked anti-rabbit IgG (1:50) for 1 h. The ﬂuo-
rescence was detected by a Nikon Diaphot 300 microscope (Nikon,
Tokyo, Japan) equipped with ﬂuorescence imaging system and true-
color digital camera (Micropublisher, QImaging, Burnaby, BC, Can-
ada).2.5. Antisense ODN treatment of PC12 cells
Based on the cDNA sequence of the murine Nischarin, two pairs of
end-capped phosphorothioate modiﬁed ODNs were designed. Anti-
sense 1 was targeted to the N-terminal of the Nischarin cDNA including
the initial code (ATG) of protein translation: 5 0C*GATGAGTGT-
TAGATTC*T3 0. (*: phosphorothioated), and the following mismatch
1 served as control: 5 0C*GTTGTGTCTTAGAATC*A3 0. Antisense 2
was designed to target the cDNA area that encodes the C-terminal of
Nischarin: 5 0T*CCACTATCCATTGCCT*G3 0, and mismatch 2 was
its control: 5 0T*CGACAATCCAAAGCCT*C3 0. All of the ODNs were
synthesized by Invitrogen. PC12 cells were sub-cultured in a 100 mm
cell culture dish coated with poly-lysine. The cells were washed and
grown in fresh media without the serum and antibiotics for 1 h. The
antisense ODN or the corresponding mismatch was mixed with oligo-
fectamine reagent (Invitrogen); and the transfection was performed
according to the manufacturer’s procedure. The transfected PC12 or
parent PC12 cells treated with or without NGF (Sigma–Aldrich, St.
Louis, MO; 50 ng/ml) for 48 h, then, treated for 15 min with or without
rilmenidine (10 lM), a selective I1-receptor agonist according to our
previous protocol [3]. The production of MAPKp42/44 reﬂected the acti-vation and function of the I1-receptor [3,4]. The concentration of rilme-
nidine and time of exposure constituted the optimal conditions for the
phosphorylation of MAPK (p42/44) elicited by the I1-receptor activa-
tion in PC12 cells [3].
2.6. Western blotting
Western blotting was performed as described previously to detect
MAPKp42/44 in PC12 cells [3]. The protein concentration in the super-
natant was quantiﬁed by a modiﬁed Lowry’s assay procedure (Bio-
Rad protein assay system). Same amount of denatured protein samples
(15 lg/lane) were electrophoresed in NuPAGE Novex 4–12% Bis-Tris
Gel (Invitrogen) and followed by electrotransfer to nitrocellulose mem-
brane (Bio-Rad Laboratories, Hercules, CA). The anti-Nischarin (NT)
antiserum and the anti-active MAPK (Promega, Madison, MI) were
diluted 1:1000. The anti-rabbit IgG-horseradish peroxidase served as
a secondary antibody. Blots were detected by enhanced chemilumines-
cence system (ECL system) and exposed to the Hyper-ﬁlm(Amersham
Biosciences, Buckinghamshire, England). The blots were quantiﬁed by
measuring the intergraded density (mean density · area) using the pub-
lic domain NIH Image(http://rsb.info.nih.gov/nih-image/). The results
were expressed as percent change from the control, and the data pre-
sented as ‘‘mean ± S.E.’’. The statistical comparisons were conducted
by one-way analysis of variance (ANOVA) followed by Turkey-Kra-
mer multiple comparisons test. P < 0.05 indicated signiﬁcant diﬀer-
ence.3. Results
Two anti-Nischarin antibodies were produced by immuniz-
ing rabbits with the synthetic peptides, which recognized the
N-terminal or C-terminal protein sequence of murine Nischa-
rin. The titers of the polyclonal antisera were checked by
ELISA and displayed the 105–106 dilution compared to the
pre-bleeding sera. To demonstrate the antibody speciﬁcity,
the peptides used for the immunization were utilized for block-
ing the binding of the rabbit anti-Nischarin antibodies follow-
ing the protocol of Alpha Diagnostic International, Inc (San
Antonio, TX). Further, the antisera were tested for their spec-
iﬁcity by comparing their pre-antisera in Western blotting and
immunohistochemistry. No detectable signal was found in
PC12 cells using the pre-antiserum of Nischarin (NT)
(Fig. 3B). The anti-Nischarin (CT) antiserum did not exhibit
any speciﬁc signal in Western blot but successfully recognized
the protein in immunohistochemistry studies (data not shown).
Therefore, in the present study, we used the N-terminal anti-
Nischarin antibody for Western blot.3.1. The expression of Nischarin in cell lines
NIH3T3 cells were transfected with full-length Nischarin
vector (pcDNA-myc-Nischarin) or empty vector (without Nis-
charin) by using lipofectamine. The expression of the Nischa-
rin was evaluated by Western blot (Fig. 1). Nischarin was
identiﬁed by anti-Nischarin (NT) antibody and displayed a
band equivalent to a molecular weigh around 190 kD, which
was similar to that previously reported by Alahari [12].
Fig. 1 also shows that, in the presence of the anti-Nischarin
antibody (NT), the diﬀerentiated PC12 cells exhibited a band
with molecular weight around 210 kD, which is very similar
to the band obtained in the Neuro 2A cells detected by chicken
anti-Nischarin antibody [12]. Immunoﬂourescence labeling of
PC12 cells with anti-Nischarin (NT) revealed stronger signal
compared with the pre-antiserum (Fig. 2A and B). The signal
in the PC12 cells seems to be associated with the membrane
rather than the cytosolic region (Fig. 2B). The control in which
Fig. 1. Expression of Nischarin in NIH3T3 and PC12 cell lines. The
NIH3T3 cells were transfected with the full length Nischarin or vector
without Nischarin by using Lipofectamine. Parent PC12 cells without
Nischarin transfection were also used. The cell lysates were separated
by the SDS–PAGE and detected by rabbit anti-Nischarin (NT)
antibody. The NIH3T3 cells transfected with Nischarin (Nis) demon-
strated a new band (arrowhead) compared with the vector (Vec) alone,
lipofectamin (Lip) alone and the parent (Par) NIH3T3. The lysate of
the parent PC12 cells showed a diﬀerent molecular weight of the
Nischarin protein (arrow) compared with transfected NIH3T3.
Fig. 3. Eﬀect of Nischarin antisense treatment on Nischarin expres-
sion. Two pairs of the antisense ODNs and their mismatches were
transfected into PC12 cells. After the SDS–PAGE and transferring to
the membrane, the anti-Nischarin (NT) antibody was utilized for
immunoblotting. Bar graphs represent the percent change
(mean ± S.E.; n = 3 each) in Nischarin expression compared to the
control group (parent PC12 cells). Antisense ODNs signiﬁcantly
reduced the expression of Nischarin compared with the control
(*P < 0.05) and corresponding mismatch ODNs (#P < 0.05). Oligofec-
tamine (Oli) or NGF alone did not aﬀect the expression of Nischarin.
(A) A representative blot showed the eﬀect of antisense ODNs on the
expression of Nischarin. (B) No signal was detected by pre-antiserum.
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ground ﬂuorescence as pre-antiserum (data no shown).
3.2. Eﬀect of antisense against Nischarin on the expression of
Nischarin and the phosphorylation of MAPK elicited by
rilmenidine in PC12 cells
Two pairs of antisense ODNs and their corresponding mis-
matches were designed and transfected into the PC12 cells. The
expression of endogenous Nischarin and the production of the
MAPKp42/44 elicited by rilmenidine were investigated by Wes-
tern blot utilizing the anti-Nischarin (NT) antibody and the
anti-active MAPK (p42/44) antibody, respectively (Fig. 3A
and 4). Compared with the control, treatment of the PC12 cells
with NGF did not aﬀect the expression of Nischarin (Fig. 3A).
Both antisense 1 and 2 substantially (P < 0.05) reduced the
expression of Nischarin (210 kD band) compared with the con-
trol or the corresponding mismatch (Fig. 3A). Although NGF
had no eﬀect on the expression of Nischarin in PC12 cells
(Fig. 3A), the diﬀerentiation of PC12 cells by NGF is required
for the phosphorylation of MAPK elicited by I1-receptor acti-
vation [3]. Importantly, the I1-agonist rilmenidine (10 lM,
15 min) evoked enhancement of phospho-MAPKp42/44 produc-
tion was signiﬁcantly (P < 0.05) attenuated by the antisense of
Nischarin compared with the control or the corresponding
mismatch (Fig. 4). The values that represent mismatch 1 and
2, in Fig. 4, were not signiﬁcantly diﬀerent from the control va-
lue. Notably, comparison of the data presented in Figs. 3 and 4
revealed a strong correlation (r = 0.99, data not shown) be-
tween the antisense-evoked reductions in Nischarin expressionFig. 2. Immunoﬂourescence detection of Nischarin in PC12 cells. The PC12 c
pre-antiserum (A), and then with FITC conjugated secondary antibody. Thand in the phosphorylation of MAPK (p42/44) elicited by I1-
receptor activation (rilmenidine).4. Discussion
In the present study, two speciﬁc antibodies against the syn-
thesized peptides of Nischarin were produced in our labora-
tory. We showed that these antibodies recognize nischarin, a
possible candidate for the I1-receptor, in PC12 cells. Using
the N-terminal antibody developed in our lab, we have identi-
ﬁed a band of approx 190 kD in NIH3T3 cells transfected with
Nischarin, which agrees with reported ﬁndings [12]. However,ells were immuno-labeled with the anti-Nischarin (NT) antibody (B) or
e scale bar of the picture is 100 lm.
Fig. 4. Eﬀect of antisense against Nischarin on rilmenidine (I1-
receptor)-evoked phosphorylation of MAPK (p42/44). PC12 cells
transfected with antisense ODNs or corresponding mismatches were
diﬀerentiated by NGF (50 ng/ml, 48 h). Rilmenidine (Ril, 10 lM,
15 min) triggered the phosphorylation of MAPK, which was detected
by anti-active MAPKp42/44 polyclonal antibody. Bar graphs illustrate
the percent changes (mean ± S.E.; n = 4 each) in the phospho-MAPK
compared to the rilmenidine alone (control) group. The antisense
against Nischarin signiﬁcantly reduced the MAPKp42/44 expression
induced by rilmenidine compared with the control (*P < 0.05) and
corresponding mismatch (#P < 0.05).
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ing a molecular weight of approx 210 kD was detected. The
ability of the antisense ODNs synthesized based on Nischarin
cDNA sequence to inhibit the expression of endogenous Nis-
charin in PC12 cells supports the speciﬁcity of the developed
antibodies. Importantly, we also demonstrate, for the ﬁrst
time, that these antisense ODNs inhibit an established signal-
ing pathway triggered by the I1-receptor in PC12 cell. To-
gether, these new ﬁndings suggest: (1) Nischarin seems to
function as the I1-receptor, at least in PC12 cells, and (2) the
newly developed antibodies, particularly the anti-Nischarin
(NT), might constitute useful tools in future Nischarin/I1-
receptor signaling studies.
Nischarin is more than 80% homologous with human IRAS
[6,12,15]. Both proteins are candidates for the I1-receptor in
diﬀerent cell lines and animal species. The cloning and charac-
terization of IRAS and Nischarin have been discussed by Piletz
[6] and Alahari et al. [12], respectively. Whether or not the
hIRAS and Nischarin are transmembrane receptor proteins
is critical for the understanding of their functions. To address
this issue, we used some of the bioinformatics models to pre-
dict transmembrane helices (TMH) of hIRAS and Nischarin.
By using dense alignment surface (DAS) method [16], the
IRAS and Nischarin proteins seem to have seven a-helices
on strict cutoﬀ (2.2), similar to the G-protein coupled receptor
proteins. By using the method of the ‘‘DAS-TM ﬁlter’’ with
low false positive rate [17], three and four trusted TMH were
found in hIRAS and Nischarin, respectively. Further analysis,
using structure alignment program for proteins (STRAP, Insti-
tute for Biochemistry Humboldt, University Berlin, Charite
Group for Protein Structure Theory), revealed that both
hIRAS and Nischarin have the conserved transmembranesequence (LMCFLIHVQGSIRQFAACLVL). Considering
the variation of the diﬀerent prediction models [6], the bioin-
formatics modeling makes it diﬃcult to equate the hIRAS
and Nischarin as G-protein coupled receptors, but may sup-
port the notion that both are transmembrane proteins. The
present and reported ﬁndings in well established cell lines seem
to strengthen this notion. In wild type and hIRAS-transfected
PC12 cells, both the membrane and cytosolic fractions con-
tained the hIRAS detected by Western blotting [9]. In our
immunoﬂourescence study using our developed anti-Nischarin
(NT) antibody, a strong labeling was associated with the mem-
brane of PC12 cells (Fig. 2B). Together, both bioinformatics
and experimental evidence support the possibility that the
IRAS and Nischarin are transmembrane proteins. Impor-
tantly, no evidence was previously sought to link the I1-recep-
tor to Nischarin.
To gain support to our hypothesis that Nischarin serves as a
functional membrane protein that shares signaling with, or
may indeed function as the I1-receptor, two types (N- and C-
terminal) of antibodies were produced in our laboratory based
on the protein sequences of murine Nischarin [12]. The speci-
ﬁcity of the antibodies was carefully analyzed by ELISA, anti-
body blocking (data not shown) and comparison with the
pre-bleeding serum (Fig. 3B). Because our preliminary studies
showed that the N-terminal antibody was superior to the
C-terminal antibody in detecting Nischarin, we utilized the
N-terminal antibody in the ODNs and I1-receptor signaling
experiments in the present study.
Results of the present study showed that the proteins de-
tected by the N-terminal antibody (approx 190 and 210 kD)
in the Nischarin transfected NIH3T3 and PC12 cells, respec-
tively (Fig. 1), were somewhat higher than the predicted mur-
ine Nischarin protein (150 kD, 1354 aa) or the hIRAS
protein (167 kD, 1504 aa) [6,12]. The reason for this disparity
is not known. It is possible that the cell type, particularly cells
that exhibit neuronal phenotype, plays a role in this disparity.
In support of this notion, in reported studies diﬀerent anti-nis-
charin or anti-IRAS antibodies [8,12] recognized proteins of
similar molecular weight (approx 210 kD) in cells with neuro-
nal phenotype and approx 190 kD in cells that do not exhibit
neuronal phenotype [12]. Notably, smaller molecular weight
proteins could be detected by our antibody (data not shown)
and by diﬀerent antibodies [18]. Nonetheless, because the
210 kD was the most prominent band, we hypothesized that
the higher molecular weight band obtained in PC12 cells would
represent a viable candidate for the I1-receptor and sought evi-
dence from pertinent signal transductions studies to support
our hypothesis. First, we and others have identiﬁed a unique
signaling pathway triggered by the I1-receptor in PC12 cells,
which leads to enhanced phosphorylation of MAPK (p42/44)
via the PC–PLC–PKC pathway [3,19,20]. Second, we have re-
cently established biological relevance for the signal transduc-
tion product, MAPKp42/44, generated by the activation of the
I1-receptor in vivo [4]. In the latter study, we have shown that
the induction of neuronal MAPK (p42/44) phosphorylation
uniquely distinguishes the I1-receptor from neuronal a2-AR.
Together, these ﬁndings yielded convincing evidence for the
utility of MAPKp42/44 as a reliable intracellular marker for
the activation of the I1-receptor in neuronal pools. It is imper-
ative to note that the PC12 cells exhibit neuronal phenotype
following diﬀerentiation with NGF, a requirement for the
generation of MAPKp42/44 by I1-receptor activation in the
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hypothesis, we investigated in PC12 cells the eﬀect of the spe-
ciﬁc Nischarin antisense ODN on the expression of the 210 kD
protein and the generation of MAPKp42/44 in response to I1-
receptor activation. Under these conditions, there was a strong
relationship (r = 0.99) between the antisense-evoked reduc-
tions in the 210 kD band and in the level of MAPKp42/44 gen-
erated by I1-receptor (rilmenidine) activation (Figs. 3 and 4).
Together, these ﬁndings suggest a link between Nischarin
and the I1-receptor.
In conclusion, we developed a new anti-nischarin antibody
to test our hypothesis that Nischarin serves as, or at least share
a common signaling pathway with, the I1-receptor. As ex-
pected, the new antibody identiﬁed the protein in Nischarin-
transfected NIH3T3 cells. Importantly, a single 210 kD band
was identiﬁed in PC12 cells incubated with this new antibody,
which might reﬂect the endogenous I1-receptor. Treatment of
PC12 cells with a speciﬁc Nischarin antisense, which virtually
abolished the 210 kD band, substantially reduced the genera-
tion of MAPKp42/44 elicited by I1-receptor activation by rilme-
nidine. The present ﬁndings suggest that Nischarin might serve
as the I1-receptor or at least shares a common signaling path-
way with the I1-receptor in diﬀerentiated PC12 cells, which ex-
hibit neuronal phenotype.
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